Kornimate/medical-research-clean huggingface dataset:
noninvasive brain stimulation to evaluate neural plasticity after stroke

Conditions: Cerebrovascular Stroke

Summary: the purpose of this study is to examine how different areas in the brain interact with each other and how using brain imaging and brain stimulation approaches can influence these interactions.

subcortical strokes affect small vessels deep in the brain, and typically present with motor hemiparesis. the investigator will assess the effects of transcranial magnetic stimulation (tms) on motor function and examine how different areas in the human brain interact with each other using brain imaging and brain stimulation. the investigator will also evaluate the capacity for noninvasive stimulation to transiently modify brain activity supporting arm movement.

Eligibility criteria:
inclusion criteria: 1. age between 18-85 years 2. middle cerebral artery stroke 3. individuals with a first time stroke that affects the corona radiata and/or internal capsule exclusion criteria: 1. age outside the age range of 18-85 years 2. signs of dementia (score \< 24 on the montreal cognitive assessment) 3. aphasia (score \< 13 on the frenchay aphasia screen) 4. history of head trauma 5. history of a major psychiatric diagnosis 6. history of a neurodegenerative disorder 7. history of substance abuse 8. contraindications to transcranial magnetic stimulation

Keywords: neural plasticity noninvasive brain stimulation motor cortex
study of two formulations of gsk biologicals' varicella vaccine

Conditions: Varicella

Summary: the aim of this study is to evaluate a modified formulation of gsk biologicals' live attenuated varicella vaccine. in vivo pre-clinical data show this change has no negative impact on vaccine safety. this present study is undertaken to rule out any negative impact on the immunogenicity and safety of gsk biologicals' live attenuated varicella virus vaccine.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study. * a male or female between, and including, 11 and 21 months of age at the time of the first vaccination. * written informed consent obtained from the parent or guardian of the subject. * healthy subjects as established by medical history and clinical examination before entering into the study. exclusion criteria: * use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. * planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days prior to the first study vaccine dose until 42 days after second study vaccine dose with the exception of oral polio vaccine (opv) which can be given at any time and routine inactivated vaccines which can be administered up to eight days before each study vaccine dose. * previous vaccination against varicella. * known history of clinical varicella. * known exposure to varicella within 30 days prior to study start. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * a family history of congenital or hereditary immunodeficiency. * history of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s), including systemic hypersensitivity to neomycin. * major congenital defects or serious chronic illness. * acute disease at the time of enrolment. all vaccines can be administered to persons with a minor illness. * axillary temperature ≥ 37.5°c / rectal temperature ≥ 38°c. * residence in the same household as a high risk person e.g.: new-born infants (0-4 weeks of age), pregnant women who have a negative history of chickenpox, persons with known immunodeficiency

Keywords: chickenpox varicella two-dose schedule second year of life
multisystem inflammatory syndrome in children at sohag university hospital

Conditions: Multisystem Inflammatory Syndrome in Children

Summary: since its initial description in december 2019 in wuhan , china, corona virus disease 2019 (covid-19), caused by infection with severe acute respiratory syndrome corona virus 2 (sars-cov-2), has rapidly evolved into a worldwide pandemic affecting millions of lives . unlike adults, the vast majority of children with covid-19 have mild symptoms. however, there are children who have significant respiratory disease, and some children may develop a hyper inflammatory response similar to what has been observed in adults with covid-19. furthermore, in late april 2020, reports emerged of children with a different clinical syndrome resembling kawasaki disease (kd) and toxic shock syndrome; these patients frequently had evidence of prior exposure to sars-cov-2. the pathophysiology of mis-c: is unclear ,but it appears to be a consequence of a exacerbated immune system response or maladaptive response of the host .after the virus enters the human cells, the first line of defense against infection should be a quick and well-coordinated immune response ;however, when this mechanism is unregulated and excessive ,hyper inflammation can occur. cytokines that play an important role in inducing immunity and immunopathology during infections in excess can cause the clinical syndrome known as cytokine storm. the inflammatory response caused by sars-cov-2appears to be the major cause of mortality in infected patients . the infection of dendritic cells or macrophages by sars-cov-2 induces the production of low levels of antiviral cytokines and increases the production of inflammatory cytokines (tumor necrosis factor\[tnf\], interleukin\[il\]-1, il-6,and interferon ).


Eligibility criteria:
inclusion criteria: any suspected case of mis-c from birth to 12 year included both sexes fulfill criteria of mis-c (who) . 1. fever for ≥3 days. 2. clinical signs of multi system involvement (at least 2 of the following): 1. rash, bilateral non purulent conjunctivitis, or mucocutaneou inflammation signs (oral, hands, or feet) 2. hypotension or shock 3. cardiac dysfunction, pericarditis, valvulitis , or coronary abnormalities (including echocardiographic findings or elevated troponin) 4. evidence of coagulopathy (prolonged pt or ptt) 5. acute gastrointestinal symptoms (diarrhea , vomiting, or abdominal pain) 4. elevated markers of inflammation (eg esr, crp) 5. no other obvious microbial cause of inflammation. 6. evidence of sars-cov-2 infection (any of the following: positive sars-cov-2 rt-pcr ,positive serology, covid 19 exposure within the 4 weeks prior to the onset of symptoms). according to cdc criteria exposure to a patients with suspected or confirmed covid-19 within the 4 weeks prior to the onset of symptoms. exclusion criteria: * other obvious microbial cause of inflammation, including bacterial sepsis and staphylococcal/streptococcal toxic shock syndromes.
phase ii gleevec idiopathic hypereosinophilic syndrome

Conditions: Eosinophilia; Hypereosinophilic Syndrome

Summary: the purpose of the trial is to determine the safety and efficacy of gleevec" in idiopathic hypereosinophilic syndrome (hes) and to characterize the molecular basis for the therapeutic benefit of gleevec" in hes.


Eligibility criteria:
inclusion criteria:- at study entry, absolute peripheral blood eosinophil count greater than upper limit of normal at the laboratory where the analysis is performed. * patients must have symptomatic disease, e.g. signs or symptoms of organ involvement related to eosinophilia. examples include pulmonary, cardiac, gi, or central nervous system disease, hepatomegaly, splenomegaly, or skin disease. * bcr-abl-negative by pcr. * patients are imatinib-naive. * ability to understand and the willingness to sign a written informed consent document. * ability to swallow capsules.\&#xa; exclusion criteria:- pregnant or nursing women. patients of childbearing potential must have a negative pregnancy test prior to initiation of study drug. male and female patients of reproductive potential must agree to employ an effective barrier method of birth control during the study and for 3 months following discontinuation of study drug. * serum creatinine \>2.0. * total serum bilirubin \>2.0 mg/dl. ast(sgot) and alt (sgpt) more than 2.5 x the upper limit of normal range (uln) at the laboratory where the analyses is performed. * presence of clonal t-lymphocyte population by pcr or southern blotting. * ecog performance status score \> or = to 3. * busulfan within 6 weeks of starting treatment. * ifn-a within 14 days of starting treatment. * low dose cytosine-arabinoside or vincristine within 14 days of starting treatment. * hydroxyurea within 1 day of starting treatment. * prednisone or other immunosuppressives (e.g. azathioprine, cyclosporine-a) within 14 days of starting treatment. * aml/all-type induction chemotherapy within 4 weeks of starting treatment * persistent peripheral blood count toxicity of grade 2 or higher after receiving aml/all-type induction chemotherapy. * treatment with other investigational agents within 28 days of starting treatment. * history of non-compliance to medical regimens. * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (grade 3 / 4 new york heart association criteria), unstable angina pectoris or cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * history of hiv-positivity.
impact of therapy dogs on child anxiety and behavior during local anesthesia for dental procedures

Conditions: Situational Anxiety; Behavior

Summary: children undergoing dental restorative or surgical procedures require injection of local anesthetic. the injection procedure is often the most anxiety-producing stimulus for children during dental care, when children demonstrate the highest level of emotional distress. several studies have investigated various interventions, such as distraction, hypnosis, and cognitive behavioral therapy to ease this stress. animal-assisted therapy (e.g. the presence of a therapy dog) may be a promising strategy for managing anxiety in young dental patients. however, no studies have explored the potential benefits of using therapy dogs specifically during the administration of local anesthesia in pediatric dental patients. the objective of this randomized controlled trial is to investigate the effects of therapy dogs on pediatric dental patients during local anesthesia administration.


Eligibility criteria:
inclusion criteria: * age range: children aged 4- to 12-years * health status: healthy children without significant medical conditions (asa i or asa ii) * dental procedure: children scheduled for at least two dental procedures requiring local anesthesia * consent: written informed consent from the parent or legal guardian * verbal assent from potential subjects age 4-9 years; written assent for children age 10-12 years exclusion criteria: * allergies: children with known allergies to dogs or animal dander * children with a fear or phobia of dogs * children with a behavioral disorder which may negatively impact response to the presence of a therapy dog * previous exposure: children who have previously undergone dental procedures with local anesthesia in the presence of a therapy dog * medical conditions: children with medical conditions that might affect their vital signs independently of the dental procedure (e.g., heart conditions) * parental discomfort: cases where parents are uncomfortable with the presence of a therapy dog during the procedure * advanced behavior guidance is indicated: children whose behavior for dntal examination is classified as "definitely negative" (frankl 1)

Keywords: animal assisted therapy pediatric dentistry local anesthesia
role of low-molecular-weight heparin in unexplained recurrent pregnancy loss

Conditions: Pregnancy Loss

Summary: using low-molecular-weight heparin (lmwh), outcomes such as live birth rate and the occurrence of pregnancy complications are some of the variables reported in some studies, with varying degrees of success. the present study aimed to compare the role of lmwh in unexplained recurrent pregnancy loss.


Eligibility criteria:
inclusion criteria: * pregnant females between 18 and 44 years of age * gestational age above 8 weeks * a history of ≥3 consecutive first trimester pregnancy losses exclusion criteria: * patients with systemic lupus erythematosus * positive igg and igm anticardiolipin antibodies * positive for thrombophilia screening * any platelet function abnormality or a previous thromboembolic event requiring anticoagulant therapy (including heparin, aspirin or warfarin) * sensitive to acetylsalicylic acid, heparin, or warfarin * patients with any genetic, anatomical, or hormonal cause of recurrent pregnancy loss
prevalence of blindness, visual impairment in chao nan area, china

Conditions: Blindness; Cataract; Visual Impairment; Refractive Errors

Summary: this study will provide a profile of blindness/visual impairment, avoidable blindness and cataract surgery service in chaonan, mainland china. we also evaluate the diagnostic accuracy of rapid assessment of avoidable blindness (raab) comparison with conventional survey.

this proposal describes a population-based study aimed at determining the prevalence of visual impairment, blindness and major causes in adults age 50 years old and above in chaonan county of guangdong province, where one of the project vision charity eye center was founded in 2009. in the proposed study, we will examine 3700 chaonan county residents aged 50 years and older, selected via a clustered, randomized sampling with probability proportional to size (pps). the cluster will be at the village level, 50 subjects aged 50 years and older will be examined in each cluster includes visual acuity, torch light, and fundus review, the major cause of blindness or visual impairment will be determined. we also randomly recruited 60% clusters,total 2250 participants, from raab survey to conduct a detailed conventional eye examination. this study will provide a profile of blindness/visual impairment, avoidable blindness and cataract surgery service in chaonan. we will evaluate the diagnostic accuracy of rapid assessment of avoidable blindness (raab) comparison with conventional survey. . it will provide important public health issues for the purposes of establishing a sustainable and suitable model to eliminate the cataract blindness in china.

Eligibility criteria:
inclusion criteria: * aged 50 years and above * in each household all persons , residing in the household for six months or more over the past year * "residing in the household" is defined as "sharing meals from the same kitchen with the other members of the household for at least 6 months in a year. exclude any visitors. exclusion criteria: * age \<50 years old * visitors in the villages * residing in the household\< 6 months

Keywords: blindness cataract blindness diagnostic accuracy
clinical study to investigate the biological activity, safety, tolerability, and pharmacokinetics of ponesimod in subjects with symptomatic chronic gvhd

Conditions: Chronic Graft Versus Host Disease

Summary: chronic graft versus host diseasre (gvhd) is a serious reaction that might occur in a person (the host) who has received cells or organs (graft) from another person because the graft attacks the host's cells. currently there are no approved therapies for chronic gvhd in the usa, and patients with chroninc gvhd are treated with immunosuppressant drugs. t-lymphocytes (a type of white blood cells) are likely to play a role in the development of chronic gvhd. due to the capacity of ponesimod to block the traffic of t-lymphocytes, ponesimod may be a new therapeutic approach to treat chroninc gvhd. the main objective of this study is to assess the effectiveness and safety of several doses of ponesimod in subjects with chronic gvhd who did not respond to standard available treatments.


Eligibility criteria:
inclusion criteria: * signed informed consent * symptomatic moderate or severe chronic gvhd patients in need of a change of systemic immunosuppressant (is) therapy * women of child bearing potential must have a negative pregnancy test and use reliable methods of contraception exclusion criteria: * clinically significant medical conditions including active or uncontrolled infections, new or recurrent malignancy, serious cardiac, pulmonary, or renal disease, and uncontrolled diabetes. * karnofsky performance score \< 60. * immunosuppressant therapies other than allowed background therapy * anti-arrhythmic and heart rate lowering drugs. * any other circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

Keywords: gvhd ponesimod
effect of radiofrequency in the treatment of de novo dyspareunia at 4 to 9 months postpartum.

Conditions: Dyspareunia

Summary: this study evaluates if the application of resistive capacitive monopolar radiofrequency therapy associated with thiele massage is effective when treating de novo dyspareunia at 4 to 9 months postpartum.

dyspareunia is a type of genito-pelvic pain (gpp) that takes place during vaginal penetration at some point in sexual intercourse. it greatly affects quality of life as well as psychological and sexual wellbeing. a delivery with episiotomy, perineal tearing or labor dystocia using forceps or vacuum, are risk factors that contribute to the appearance of de novo dyspareunia with a prevalence of 17-45% at 6 months postpartum. there is no evidence in the scientific literature of the effect of radiofrequency is this group of patients, however there is a clinical trial that describes the effect in scar tissue although not in the perineum. it is for all of the above that the following project is proposed, to evaluate the effect of rf in perineal healing and vaginal trigger points caused as a consequence of gpp. the main objective of this study is to evaluate the role that radiofrequency (rf) plays in reducing the level of pain in de novo dyspareunia in postpartum women that persists from 4 to 9 months.

Eligibility criteria:
inclusion criteria: * 4-9 postpartum * de novo dyspareunia after delivery * obstetric injury * grant informed consent exclusion criteria: * radiofrequency contraindications (pacemaker, active infection or pregnancy) * cesarean section * dyspareunia previous to labour * previous vulvo-vaginal pathology * patients with postpartum depression * patients with a pelvic region oncological history

Keywords: dyspareunia radiofrequency postpartum pain perineal massage episiotomy
does azithromycin cause qt prolongation in hospitalized patients with severe community acquired pneumonia?

Conditions: Pneumonia

Summary: the macrolide group of antibiotics can cause qt prolongation, and endanger the patient with life threatening arrythmias. qt prolongation caused by azythromycin, a relatively new macrolide, is extremely rare, and was not reported in clinical trials. our hypothesis is that patients hospitalized with severe community acquired pneumonia, usually with multiple comorbid conditions will have a higher rate of qt prolongation, compared to the clinical trials published

patients hospitalized with community aquired pneumonia will have their corrected qt measured daily during antibiotic therapy. concomittant medications and electrolyte abnormalities that cause prolonged qt will be recorded

Eligibility criteria:
inclusion criteria: * severe community acquired pneumonia * treated with azithromycin * age over 18 years exclusion criteria: * azithromycin initiated before hospitalization * technically undecipherable ecg * permanent pacemaker

Keywords: qt prolongation azithromycin macrolide pneumonia ecg changes
a comparison of diabetes group education as administered through telemedicine versus as administered in person

Conditions: Diabetes Mellitus

Summary: this study compares group diabetes education in-person versus via telemedicine

diabetes education is important in the treatment of the person with diabetes. a diabetes self-management education program not only educates the patient and his/her family to the basics of diabetes care but also integrates diabetes care into daily life while providing coping skills to adjust to this chronic illness. unfortunately, comprehensive diabetes care is not available to all persons with diabetes. one obstacle to the provision of comprehensive diabetes care is the unavailability of a diabetes treatment center. many people with diabetes live too far or do not have the transportation to be able to attend education programs that met national standards. we have shown that telemedicine is an effective means to provide comprehensive 1:1 individualized diabetes education to persons with diabetes. we now propose to test the hypothesis that diabetes groups education classes can be provided effectively through telemedicine technology to individuals living in rural areas. patients with diabetes will received diabetes education via teleconferencing from our joslin diabetes center. the participants will be assessed before and after diabetes education via telemedicine using measures of glycemia (a1c) and assessments of patient satisfaction, emotional well being, and behavioral change and compared to results from participants attending our diabetes education classes in-person.

Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes mellitus * age \> 18 years exclusion criteria: * profound vision loss * severe hearing impairment

Keywords: diabetes education telemedicine
3d analysis of root canal conformation

Conditions: Endodontic Disease; Root Canal Infection

Summary: aim to evaluate in vivo the shaping ability of the canal with 3 different single-file systems: reciproc blue, waveone gold and xp endo-shaper, using cone beam computed tomography and 3d reconstructions to measure canal volume increase, centering ability of the instruments and canal transportation in human premolars in vivo. methodology thirty human lower premolars were randomly divided into three groups, in which root canals were prepared using one of these single-file systems: reciproc blue, waveone gold, and xp endoshaper. root canals were scanned before and after root canal preparation by using cbct and 3d reconstruction was carried out to evaluate canal volume increase, centering ability of the instrument and canal transportation for each group. statistical analysis was made for each variable to determine statistically significant differences between groups.


Eligibility criteria:
inclusion criteria: 1. 18-30 years old 2. healthy conditions 3. not medicated with any type of drug 4. non-smoking patients 5. lower premolars indicated for extraction due to orthodontic reasons 6. lower premolar with more than one root canal exclusion criteria: 1. not willing to participate 2. pregnant women 3. lower premolars with previous root canal therapy 4. lower premolars with

Keywords: root canal preparation single-file preparation techniques 3d reconstruction